![Sarv BioLabs Hyoscine Butyl Bromide](https://www.pharmacompass.com/image/flap/sarv-biolabs-hyoscine-butyl-bromide-desktop-headergif-23556.gif)
![Sarv BioLabs Hyoscine Butyl Bromide](https://www.pharmacompass.com/image/flap/sarv-biolabs-hyoscine-butyl-bromide-mobgif-91620.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Cara Care has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany to provide Sanofi’s Buscomint® bei Reizdarm drug with Cara Care’s digital companion app for digestive conditions.
Lead Product(s): Hyoscine Butyl Bromide
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020